Finding 1167968 (2024-002)

Material Weakness Repeat Finding
Requirement
B
Questioned Costs
-
Year
2024
Accepted
2026-01-06
Audit: 379617
Organization: Montana Cancer Consortium (MT)
Auditor: KCOE ISOM LLP

AI Summary

  • Core Issue: Inadequate documentation and lack of independent review for expenditures, particularly those made by the director.
  • Impacted Requirements: Noncompliance with 2 CFR § 200.303 regarding effective internal controls over federal awards.
  • Recommended Follow-Up: Strengthen internal controls by requiring complete documentation, implementing a formal review process, and ensuring independent approval for director expenditures.

Finding Text

#2024-002: Grant Program: Department of Health and Human Services – National Institutes for Health Research and Development Cluster – Cancer Control – Assistance Listing #93.599 – Lack Inadequate Documentation and Lack of Independent Review of Expenditures Condition: During the audit for the fiscal year ended May 31, 2024, transactions lacked sufficient supporting documentation or evidence of review and approval by the director. Additionally, some of the expenditures were incurred by the director and were self-reviewed without any independent oversight or secondary approval. Criteria: Per 2 CFR § 200.303, nonfederal entities must establish and maintain effective internal control over federal awards that provide reasonable assurance that the organization is managing the awards in compliance with federal statutes, regulations, and the terms and conditions of the award. Effective internal controls include proper documentation and independent review of expenditures to ensure allowability, reasonableness, and compliance. Context: Out of 61 expenditures tested, 28 lacked sufficient supporting documentation or evidence of review. 21 of the 28 were expenditures incurred by the director and self-reviewed. Cause: The Consortium has not implemented adequate internal control procedures to ensure that all expenditures are properly documented and independently reviewed. The lack of segregation of duties, particularly in the review of expenditures made by the director, contributed to the deficiency. Effect: The absence of sufficient documentation and independent review increases the risk of unauthorized, unsupported, or unallowable expenditures. Recommendation: We recommend that the Consortium strengthen its internal control procedures by: • Requiring complete supporting documentation for all expenditures; • Implementing a formal review and approval process for all transactions, including those made by executive leadership; and • Ensuring that expenditures made by the director are reviewed and approved by an independent party, such as a board member or designated individual. Management Response: See Corrective Action Plan.

Corrective Action Plan

Finding #2024-002: Grant Program: Department of Health and Human Services – National Institutes for Health Research and Development Cluster – Cancer Control – Assistance Listing #93.599 – Lack Inadequate Documentation and Lack of Independent Review of Expenditures Corrective Action: We agree with the recommendation. We do currently require complete supporting documentation for all expenditures. MCC has updated the Financial Process Procedure to include language related to receipt management, and allowable and disallowed grant expenses. MCC has created a Travel Reimbursement Procedure that addresses approval of Director expenses. Timeline: This was implemented on December 1, 2025. Responsible Parties: MCC Director, Principal Investigators

Categories

Internal Control / Segregation of Duties Allowable Costs / Cost Principles

Other Findings in this Audit

  • 1167967 2024-001
    Material Weakness Repeat
  • 1167969 2024-003
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.399 CANCER CONTROL $906,601